Glycoprotein News and Research

RSS

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

24 May 2012

ScreenCell, Affymetrix partner to distribute CTC platform

Affymetrix, Inc. and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

18 May 2012

Quasi-experimental data supports argument that air pollution may be a global risk factor for CVD

During the 2008 Beijing Olympics, changes in air pollution were associated with changes in biomarkers of systemic inflammation and thrombosis (formation of blood clot) as well as measures of cardiovascular physiology in healthy young persons, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.

16 May 2012

Combination of vaccine and letrozole effectively improves survival from breast cancer

A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy against breast cancer, significantly increased survival when tested in mice, a team of UC Davis investigators has found.

16 May 2012

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.

2 May 2012

Researchers describe novel mechanism of HIV-1 spread by dendritic cells

A new understanding of the initial interactions of human immunodeficiency virus type 1 (HIV-1) and dendritic cells is described by Boston University School of Medicine (BUSM) researchers in a study currently featured in the Proceedings of the National Academy of Sciences.

24 Apr 2012

Differentiated luminal-like breast cancer cells can generate larger tumors

New findings in breast cancer research by an international team of scientists contradict the prevailing belief that only basal-like cells with stem cell qualities can form invasive tumors. Research led by Ole William Petersen at the University of Copenhagen (CU) and Mina Bissell of the Lawrence Berkeley National Laboratory (Berkeley Lab) and has shown that luminal-like cells with no detectable stem cell qualities can generate larger tumors than their basal-like counterparts.

19 Apr 2012

Autologous HSPPC-96 vaccine clinically beneficial for GBM patients

Study results from a Phase II multicenter clinical trial tracking the impact that autologous heat shock protein-peptide vaccine (HSPPC-96) has on recurrent glioblastoma multiforme (GBM) patients showed that such a vaccine may be clinically beneficial.

18 Apr 2012

Natural products isolated from marine mollusks and sponges can reverse multidrug resistance in cancer cells

Many marine natural products show anticancer activity, but some can reverse multidrug resistance in cancer cells. A new investigation by Robert J. Capon of the University of Queensland correlates the products' structures with their activity.

12 Apr 2012

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University.

5 Apr 2012

Study: Functional link between two major causes of treatment failure in breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows a functional link between two major causes of treatment failure in breast cancer, showing the protein behind one of these causes plays a role in increasing the drug resistance properties of the other.

4 Apr 2012

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

The Cardiovascular Research Foundation (CRF) today announced the initiation of the HORIZONS-AMI II randomized trial, evaluating Promus Element platinum-chromium everolimus-eluting stents versus Omega bare-metal stents in patients with heart attack undergoing primary angioplasty with bivalirudin anticoagulation.

28 Mar 2012

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Escherichia coli - a bacteria considered the food safety bane of restaurateurs, grocers and consumers - is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster.

27 Mar 2012

CUMC scientists develop a way to recreate personalized immune mouse

Columbia University Medical Center (CUMC) scientists have developed a way to recreate an individual's immune system in a mouse. The "personalized immune mouse" offers researchers an unprecedented tool for individualized analysis of abnormalities that contribute to type 1 diabetes and other autoimmune diseases, starting at the onset of disease.

15 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

Epigenetic mechanisms maintain tolerance in T cells specific for self antigens

At the most basic level, the immune system must distinguish self from non-self, that is, it must discriminate between the molecular signatures of invading pathogens (non-self antigens) and cellular constituents that usually pose no risk to health (self-antigens).

14 Feb 2012

Single fibronectin injection can prevent chronic pain development after SCI

Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes.

9 Feb 2012

CTI receives U.S. Patent Allowance for GlycoPolymer technology

Cell Therapeutics, Inc. (CTI) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence.

21 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Celldex third quarter net loss increases to $11.8 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011. Celldex reported a net loss of $11.8 million, or $0.27 per share, for the third quarter of 2011 compared to a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010.

2 Nov 2011